Corvus Pharmaceuticals, INC 10-K annual reports
Annual reports — audited financials, the full risk-factor list, and management’s account of the year.
NASDAQ
Corvus Pharmaceuticals reports a significant net loss for 2024 and expresses substantial doubt about its ability to continue as a going concern.
NASDAQ
10-K: Corvus Pharmaceuticals Reports Full Year 2023 Results, Outlines Path Forward for Key Drug Candidates
Corvus Pharmaceuticals details its 2023 financial results and provides updates on the clinical development of its lead drug candidates, including soquelitinib, ciforadenant, and mupadolimab.